A Belgian company wants to create woolly-mammoth burgers
DNA from extinct species is inspiring other business plans, too
Related Articles
Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study
MicroabstractTreatment options for patients with relapsed/refractory multiple myeloma (RRMM) after relapse from allogeneic stem cell transplant (alloSCT) are needed. This study provides data around suitability…
Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis
FLC-MS can detect persistent light chains in a significant proportion of patients in a conventional hematologic CR.Patients with no detectable FLC by FLC-M
Clonal Hematopoiesis of Indeterminate Potential in Patients with Immunoglobulin Light Chain AL Amyloidosis
Key Points. CHIP is more prevalent in AL amyloidosis patients than in the general populationCHIP presence was associated with the presence of t(11;14) and
Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1
Key Points. Better clinical responses to teclistamab correlate with a more functional initial immune T-cell repertoire in the periphery and tumor siteMore
Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma
Teclistamab is effective in real-world patients with R/RMM, including those with prior anti-BCMA therapy exposure, albeit with slightly poorer progression-
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma
Teclistamab is effective in real-world patients with R/RMM, including those with prior anti-BCMA therapy exposure, albeit with slightly poorer progression-
Patterns of CRS with Teclistamab in Relapsed/Refractory Multiple Myeloma patients with Prior T-Cell Redirection Therapy
Key Points. Multiple myeloma patients previously treated with T-cell redirection therapy have significantly low risk of developing CRS with teclistamabPati